Evaluation of a 5-Tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data: Inter-reviewer variability and promotion of minimum reporting guidelines

Logan C. Walker, Phillip J. Whiley, Claude Houdayer, Thomas V O Hansen, Ana Vega, Marta Santamarina, Ana Blanco, Laura Fachal, Melissa C. Southey, Alan Lafferty, Mara Colombo, Giovanna De Vecchi, Paolo Radice, Amanda B. Spurdle

Research output: Contribution to journalArticle

Abstract

Splicing assays are commonly undertaken in the clinical setting to assess the clinical relevance of sequence variants in disease predisposition genes. A 5-tier classification system incorporating both bioinformatic and splicing assay information was previously proposed as a method to provide consistent clinical classification of such variants. Members of the ENIGMA Consortium Splicing Working Group undertook a study to assess the applicability of the scheme to published assay results, and the consistency of classifications across multiple reviewers. Splicing assay data were identified for 235 BRCA1 and 176 BRCA2 unique variants, from 77 publications. At least six independent reviewers from research and/or clinical settings comprehensively examined splicing assay methods and data reported for 22 variant assays of 21 variants in four publications, and classified the variants using the 5-tier classification scheme. Inconsistencies in variant classification occurred between reviewers for 17 of the variant assays. These could be attributed to a combination of ambiguity in presentation of the classification criteria, differences in interpretation of the data provided, nonstandardized reporting of results, and the lack of quantitative data for the aberrant transcripts. We propose suggestions for minimum reporting guidelines for splicing assays, and improvements to the 5-tier splicing classification system to allow future evaluation of its performance as a clinical tool.

Original languageEnglish
Pages (from-to)1424-1431
Number of pages8
JournalHuman Mutation
Volume34
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Computational Biology
Guidelines
Publications
Research
Genes

Keywords

  • BRCA1
  • BRCA2
  • Classification
  • Splicing assays

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Evaluation of a 5-Tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data : Inter-reviewer variability and promotion of minimum reporting guidelines. / Walker, Logan C.; Whiley, Phillip J.; Houdayer, Claude; Hansen, Thomas V O; Vega, Ana; Santamarina, Marta; Blanco, Ana; Fachal, Laura; Southey, Melissa C.; Lafferty, Alan; Colombo, Mara; De Vecchi, Giovanna; Radice, Paolo; Spurdle, Amanda B.

In: Human Mutation, Vol. 34, No. 10, 10.2013, p. 1424-1431.

Research output: Contribution to journalArticle

Walker, LC, Whiley, PJ, Houdayer, C, Hansen, TVO, Vega, A, Santamarina, M, Blanco, A, Fachal, L, Southey, MC, Lafferty, A, Colombo, M, De Vecchi, G, Radice, P & Spurdle, AB 2013, 'Evaluation of a 5-Tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data: Inter-reviewer variability and promotion of minimum reporting guidelines', Human Mutation, vol. 34, no. 10, pp. 1424-1431. https://doi.org/10.1002/humu.22388
Walker, Logan C. ; Whiley, Phillip J. ; Houdayer, Claude ; Hansen, Thomas V O ; Vega, Ana ; Santamarina, Marta ; Blanco, Ana ; Fachal, Laura ; Southey, Melissa C. ; Lafferty, Alan ; Colombo, Mara ; De Vecchi, Giovanna ; Radice, Paolo ; Spurdle, Amanda B. / Evaluation of a 5-Tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data : Inter-reviewer variability and promotion of minimum reporting guidelines. In: Human Mutation. 2013 ; Vol. 34, No. 10. pp. 1424-1431.
@article{fd6fb5fcdda94f6da8460dbcbae3c155,
title = "Evaluation of a 5-Tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data: Inter-reviewer variability and promotion of minimum reporting guidelines",
abstract = "Splicing assays are commonly undertaken in the clinical setting to assess the clinical relevance of sequence variants in disease predisposition genes. A 5-tier classification system incorporating both bioinformatic and splicing assay information was previously proposed as a method to provide consistent clinical classification of such variants. Members of the ENIGMA Consortium Splicing Working Group undertook a study to assess the applicability of the scheme to published assay results, and the consistency of classifications across multiple reviewers. Splicing assay data were identified for 235 BRCA1 and 176 BRCA2 unique variants, from 77 publications. At least six independent reviewers from research and/or clinical settings comprehensively examined splicing assay methods and data reported for 22 variant assays of 21 variants in four publications, and classified the variants using the 5-tier classification scheme. Inconsistencies in variant classification occurred between reviewers for 17 of the variant assays. These could be attributed to a combination of ambiguity in presentation of the classification criteria, differences in interpretation of the data provided, nonstandardized reporting of results, and the lack of quantitative data for the aberrant transcripts. We propose suggestions for minimum reporting guidelines for splicing assays, and improvements to the 5-tier splicing classification system to allow future evaluation of its performance as a clinical tool.",
keywords = "BRCA1, BRCA2, Classification, Splicing assays",
author = "Walker, {Logan C.} and Whiley, {Phillip J.} and Claude Houdayer and Hansen, {Thomas V O} and Ana Vega and Marta Santamarina and Ana Blanco and Laura Fachal and Southey, {Melissa C.} and Alan Lafferty and Mara Colombo and {De Vecchi}, Giovanna and Paolo Radice and Spurdle, {Amanda B.}",
year = "2013",
month = "10",
doi = "10.1002/humu.22388",
language = "English",
volume = "34",
pages = "1424--1431",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Evaluation of a 5-Tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data

T2 - Inter-reviewer variability and promotion of minimum reporting guidelines

AU - Walker, Logan C.

AU - Whiley, Phillip J.

AU - Houdayer, Claude

AU - Hansen, Thomas V O

AU - Vega, Ana

AU - Santamarina, Marta

AU - Blanco, Ana

AU - Fachal, Laura

AU - Southey, Melissa C.

AU - Lafferty, Alan

AU - Colombo, Mara

AU - De Vecchi, Giovanna

AU - Radice, Paolo

AU - Spurdle, Amanda B.

PY - 2013/10

Y1 - 2013/10

N2 - Splicing assays are commonly undertaken in the clinical setting to assess the clinical relevance of sequence variants in disease predisposition genes. A 5-tier classification system incorporating both bioinformatic and splicing assay information was previously proposed as a method to provide consistent clinical classification of such variants. Members of the ENIGMA Consortium Splicing Working Group undertook a study to assess the applicability of the scheme to published assay results, and the consistency of classifications across multiple reviewers. Splicing assay data were identified for 235 BRCA1 and 176 BRCA2 unique variants, from 77 publications. At least six independent reviewers from research and/or clinical settings comprehensively examined splicing assay methods and data reported for 22 variant assays of 21 variants in four publications, and classified the variants using the 5-tier classification scheme. Inconsistencies in variant classification occurred between reviewers for 17 of the variant assays. These could be attributed to a combination of ambiguity in presentation of the classification criteria, differences in interpretation of the data provided, nonstandardized reporting of results, and the lack of quantitative data for the aberrant transcripts. We propose suggestions for minimum reporting guidelines for splicing assays, and improvements to the 5-tier splicing classification system to allow future evaluation of its performance as a clinical tool.

AB - Splicing assays are commonly undertaken in the clinical setting to assess the clinical relevance of sequence variants in disease predisposition genes. A 5-tier classification system incorporating both bioinformatic and splicing assay information was previously proposed as a method to provide consistent clinical classification of such variants. Members of the ENIGMA Consortium Splicing Working Group undertook a study to assess the applicability of the scheme to published assay results, and the consistency of classifications across multiple reviewers. Splicing assay data were identified for 235 BRCA1 and 176 BRCA2 unique variants, from 77 publications. At least six independent reviewers from research and/or clinical settings comprehensively examined splicing assay methods and data reported for 22 variant assays of 21 variants in four publications, and classified the variants using the 5-tier classification scheme. Inconsistencies in variant classification occurred between reviewers for 17 of the variant assays. These could be attributed to a combination of ambiguity in presentation of the classification criteria, differences in interpretation of the data provided, nonstandardized reporting of results, and the lack of quantitative data for the aberrant transcripts. We propose suggestions for minimum reporting guidelines for splicing assays, and improvements to the 5-tier splicing classification system to allow future evaluation of its performance as a clinical tool.

KW - BRCA1

KW - BRCA2

KW - Classification

KW - Splicing assays

UR - http://www.scopus.com/inward/record.url?scp=84884530215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884530215&partnerID=8YFLogxK

U2 - 10.1002/humu.22388

DO - 10.1002/humu.22388

M3 - Article

C2 - 23893897

AN - SCOPUS:84884530215

VL - 34

SP - 1424

EP - 1431

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 10

ER -